ArticleFrontiers in oncology2026
The impact of pretransplant consolidation chemotherapy on clinical outcomes in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a single-center retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lymphoblastic leukemia (ALL) is a malignant hematological disease that accounts for approximately 20% of adult leukemia. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently recognized as one of potentially curative treatments for ALL. Though pretransplant consolidation chemotherapy is generally considered essential, there is limited research on the optimal number of consolidation cycles, which leaves the ideal timing for transplant unclear. In this study, we retrospectively analyzed the clinical outcomes of 40 adult patients diagnosed with Philadelphia chromosome-negative ALL (Ph-negative ALL) who underwent allo-HSCT at our center between January 2014 and May 2025. Among these patients, eighteen received a single cycle of consolidation chemotherapy prior to transplant, while 22 underwent multiple cycles. No statistically significant differences were observed between the single and multiple consolidation groups in terms of overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR), or non-relapse mortality (NRM). The single consolidation group demonstrated 3-year OS rates of 57%, compared to 56% in the multiple consolidation group (p = 0.83). For DFS, the single consolidation group showed 3-year rates of 51%, versus 52% in the multiple group (p = 0.97). Regarding CIR, the single consolidation group had 3-year rates of 18%, compared to 28% in the multiple group (p = 0.48). In terms of NRM, the single consolidation group exhibited 3-year rates of 25%, versus 20% in the multiple group (p = 0.45). Our real-world findings indicate that a single cycle of pretransplant consolidation chemotherapy yields comparable clinical outcomes compared to multiple cycles. These results provide valuable evidence for potentially shortening the overall treatment duration for adult patients with Ph-negative ALL and may assist clinicians in determining the optimal timing for transplant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.